Spyre Therapeutics Inc

SYRE

Equity

ISIN null / Valor 129513338

NASDAQ (2026-01-30)

USD 31.98-4.76%

Spyre Therapeutics Inc
UMushroom community rating:

3.68 7 votes No rating yet

NegativeNeutralPositive

About company

Spyre Therapeutics Inc is a biotechnology company focused on developing innovative treatments for immune-mediated diseases, particularly Inflammatory Bowel Disease (IBD). The company is engaged in the creation of advanced antibodies and therapeutic combinations, leveraging precision immunology to enhance treatment efficacy and patient convenience. By concentrating on these areas, Spyre Therapeutics aims to address significant unmet medical needs in the field of immunology, offering potential breakthroughs in the management of complex immune disorders.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

43.6%1Y

165%3Y

-81.6%5Y

Performance

69.4%1Y

117%3Y

126%5Y

Volatility

2481 M

Market cap (USD)

535,775

Daily traded volume (Shares)

23.35 / 22.37

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.68

7 votes

Performance:

2.87

Innovation:

3.19

Society:

3.45

Nature:

2.97

Mehmet John Evans

United Kingdom, 08 Nov 2025

good

Antonio Tramacere

United Kingdom, 07 Nov 2025

Under valued stock

Elsa Mhangami

United Kingdom, 05 Nov 2025

Spyre Therapeutics is a compelling innovation play with possibly high upside if its pipeline succeeds, but the risk is significant and the fundamentals (revenue, profitability, commercial track record) are not yet established.

EQUITIES OF THE SAME SECTOR

Worldline SA